《2025浦东新区生物医药产业人才发展趋势报告》发布

Core Insights - The "2025 Pudong New Area Biomedicine Industry Talent Development Trend Report" was officially released, analyzing the talent status, development trends, and future demands in the biomedicine industry of Pudong New Area based on a database of 140,000 biomedicine talents [1] - The biomedicine industry in China is at a critical stage of innovation-driven and international development, which poses higher requirements for talent development and presents new opportunities and challenges [1] Group 1 - Pudong has established itself as a major hub for Shanghai's biomedicine industry, with a complete industrial chain, excellent ecosystem, and talent aggregation, further enhancing the influence of the "Zhangjiang Pharma Valley" brand [1] - In 2023, Pudong has seen the launch of 7 Class 1 innovative drugs and 6 innovative medical devices, with a continuous emergence of "3F" innovative products, including globally first, China first, and clinically first applications [1] Group 2 - Pudong is promoting industrial upgrades through institutional innovation, aiming to become a global hub for innovative drug and device launches, a preferred location for scientists to start businesses, and a pioneer in institutional reforms [2] - The area is developing a 2-square-kilometer innovation zone along Gaoke Middle Road, focusing on gathering high-energy innovation entities such as universities, research institutions, multinational R&D centers, and high-quality incubators [2] - Pudong is enhancing its service framework by establishing the Zhangjiang Pharma Valley comprehensive service center, creating a full-chain service system that integrates space and services [2] - Future plans include strengthening source innovation, optimizing industrial space, nurturing leading enterprises, improving the industrial ecosystem, enhancing clinical review efficiency, and accelerating financial and talent support to establish a new high ground for biomedicine industry development [2]